In contrast to a period when promotion and fluff have grabbed the attention of novice stock investors interested in the legal cannabis theme since early 2013, we are now seeing companies with …
Tag: GW Pharma
Overexposed Cannabis ETF Hit Hard by Biotech Losses
Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ) (OTC: HMLSF) has been hit hard over the past two weeks, declining 8.4% since July 26th despite what has been a stable market for …
GW Pharma Epidiolex FDA Filing Delay Disappoints Investors
GW Pharma (NASDAQ: GWPH) issued a press release after the close of trading on Monday to report its FY17-Q3 financials and provide an operational update. The most significant news was …
5 U.S. Cannabis Stocks on Track for >$10mm Annual Revenue
As the U.S. cannabis industry has evolved over the past few years, so has the market for publicly-traded cannabis stocks. In 2014, very few publicly-traded companies were reporting substantial revenue. …
Horizons Medical Marijuana ETF to Debut April 5th
Let’s face it, when it comes to cannabis stocks, Canada continues to crush the United States, where federal illegality makes it more difficult to operate and to raise capital. While …
GW Pharma’s Epidiolex Receives Orphan Drug Designation in Europe
GW Pharmaceuticals Announces Epidiolex(R) Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceutical…
Stetson University Investment Fund Adds Cannabis Stocks to its Portfolio
The Roland George Investments Program (RGIP), a student-managed portfolio worth $3.5 million at Stetson University in Florida, is investing in the cannabis industry. The program, headed by Dr. K.C. Ma …
GW Pharma Clarifies State Lobbying Efforts in Advance of Epidiolex Approval
Earlier this week, we highlighted a story published on Leafly regarding lobbying efforts by GW Pharma (NASDAQ: GWPH). Leafly’s Bruce Barcott discovered that GW Pharma and its U.S. subsidiary, Greenwich …
GW Pharma Moves to Potentially Monopolize CBD Market
Note: We published a follow up to this article Leafly’s Bruce Barcott has uncovered some actions taken by GW Pharma (NASDAQ: GWPH) that appear to be part of an effort …
GW Pharma Reports FY17-Q1 Financials
GW Pharmaceuticals plc Reports First Quarter 2017 Financial Results and Operational Progress Epidiolex® NDA submission and launch preparation on track New Positive Phase 2 glioma data further demonstrates value of …
GW Pharma Reports Success with THC and CBD Combo in Brain Cancer Phase 2 Clinical Trial
GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma GW intends to advance oncology research and development efforts LONDON, Feb. 07, 2017 (GLOBE NEWSWIRE) — …
GW Pharma Ends FY16 with $483mm in Cash
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress – Three Positive Phase 3 Epidiolex clinical trials reported in 2016 – – NDA submission and …
GW Pharma Progresses Towards Epidiolex FDA Submission
GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes key …
GW Pharma Unit Greenwich Biosciences to Present Epidiolex Data at American Society of Epilepsy Annual Meeting
GW Pharmaceuticals plc Announces Epidiolex(R) (cannabidiol) Data Presentations and Educational Programs at the American Society of Epilepsy Annual Meeting – Presentations include clinical results from Phase 3 prog…
Risk Rises for U.S. Cannabis Penny Stocks
The publicly-traded cannabis stocks have enjoyed an immense rally that began on 9/1, fueled by speculation regarding this week’s legalization ballot initiatives in Arizona, California, Maine, Massachusetts and Neva…
GW Pharma Outsources Cannabis Cultivation for Epidiolex to British Sugar
Wissington glasshouse to grow plants for epilepsy medicine Wissington, Norfolk – 25 October 2016 British Sugar, the leading UK beet sugar producer, announces today that its horticultural business is to …
GW Pharma to Drop Dual Listing and Trade Only on NASDAQ
GW Pharmaceuticals plc Announces Intention to Continue Trading Exclusively on NASDAQ and Planned Cancellation of Trading of Ordinary Shares on AIM GW remains headquartered in UK and continues to expand …
Goldman Sachs Suggests Potential GW Pharma Acquisition Price of $349
Goldman Sachs initiated coverage on GW Pharma (NASDAQ: GWPH) (AIM: GWP) on October 7th, with a “Buy” rating and a target of $189. The target was based on blend of …
GW Pharma’s Epidiolex Achieves Statistical Significance in Third Phase 3 Trial for Treatment of Rare Pediatric Epilepsy
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved in both Epidiolex doses with high statistical …
Leading Investment Bank Issues Bullish Cannabis Industry Research Report
Cowen and Company released an extensive report on the cannabis industry today, suggesting the recreational market could grow to $50 billion by 2026. While this isn’t the first time that …
GW Pharma Soars on Takeover Rumors
Shares in GW Pharma (NASDAQ: GWPH) (AIM: GWP) shot up in trading today after Reuters posted an exclusive report that the company has hired investment bank Morgan Stanley in response …
GW Pharma Reports Positive Epidiolex Pre-NDA Meeting with FDA
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress – Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) – – Positive FDA pre-NDA meeting …
GW Pharma Epilepsy Research in Australia Receives $6mm Government Funding Support
With the completion of two Phase 3 clinical trials that showed its Epidiolex to be safe and effective, global interest in GW Pharma’s (NASDAQ: GWPH) pharmaceutical-grade cannabidiol (CBD) extracted from cannabis co…
GW Pharma Closes $290mm Stock Sale
GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option to …
GW Pharma Upsizes Deal and Sells 2.8mm shares at $90 to Raise $252mm
GW Pharma (NASDAQ: GWPH) announced this evening that is has priced a secondary offering at $90, raising $252mm by selling 2.8mm shares. The underwriters include Morgan Stanley, BofA Merrill Lynch, …
